Valuation dashboard for Harmony Biosciences Holdings, Inc. (HRMY) with P/E 12.02, P/B 2.14, EV/EBITDA 6.4 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc.
Analysis Summary
Harmony Biosciences Holdings, Inc. reported revenue of $868.5M in the most recent fiscal year, growing at a 5-year CAGR of 40.3%.
Trailing-twelve-month margins: gross margin 75.4%, operating margin 24.0%, net margin 18.9%.
At $37.02 (closing price, November 3, 2026), HRMY trades at a P/E of 12.02 and an ROE of 20.06%. Market capitalisation stands at $2.2B.
Balance sheet quality for HRMY: debt-to-equity ratio of 0.15, current ratio of 3.48 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 12.02 |
| Price / Book | 2.14 |
| EV / EBITDA | 6.4 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $2.2B | 12.02 | 2.14 | 20.1% |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $56.7B | 42.51 | 6.74 | 16.9% |
| 0QNO.L | Lonza Group AG | CHF 43.8B | 5.43 | -1.3% |
Price
| Price | $37.02 (closing price, November 3, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 20.06% |
| Return on Invested Capital | 14.96% |
| Return on Assets | 13.20% |
| Gross Margin | 75.42% |
| Operating Margin | 24.03% |
| Net Margin | 18.88% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of HRMY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks